CHRISTUS Health Upgrades Patient Monitoring to Pulse Oximetry Technology

Covidien has announced that CHRISTUS Health is converting to the company’s Nellcor™ pulse oximetry technology to increase patient safety. Pulse oximeters may provide early warning of dangerous respiratory complications, enabling clinicians to detect and address life-threatening events sooner.            

“We carefully assessed competing technologies and found that Nellcor was able to detect the onset of respiratory depression at an earlier time,” said Ed Hardin, CHRISTUS Health vice president of Supply Chain. “CHRISTUS Health is committed to changing lives, advancing medicine and improving access to the highest level of care for our patients and this product supports these goals.”

Nellcor pulse oximetry technology can effectively monitor a wide range of patients even when signal interference is present. Covidien is the first company to receive FDA clearance for a motion-tolerant bedside pulse oximeter that is also compliant with ISO 80601-2-61 (International Organization for Standardization standards for pulse oximetry).  

“It is terrific to partner with institutions that are as forward looking and as committed to quality and patient safety as CHRISTUS Health. Together we are working to provide monitoring solutions that benefit patients and their families,” said Doug Bartlett, vice president, U.S. Sales and Marketing, Patient Monitoring, Respiratory and Monitoring Solutions, Covidien.

CHRISTUS Health, an international Catholic, not-for-profit health system, is headquartered in Dallas and comprised of almost 350 services and facilities, including more than 60 hospitals and long-term care facilities, 175 clinics and outpatient centers, and dozens of other health ministries and ventures. CHRISTUS services can be found in more than 60 U.S cities in Texas, Arkansas, Iowa, Louisiana, Georgia and New Mexico, and in international ministries in Mexico and Chile.